Literature DB >> 27925151

Development of a clinical diagnostic matrix for characterizing inherited epidermolysis bullosa.

V K Yenamandra1, C Moss2, V Sreenivas3, M Khan4, S Sivasubbu5, V K Sharma1, G Sethuraman1.   

Abstract

BACKGROUND: Accurately diagnosing the subtype of epidermolysis bullosa (EB) is critical for management and genetic counselling. Modern laboratory techniques are largely inaccessible in developing countries, where the diagnosis remains clinical and often inaccurate.
OBJECTIVES: To develop a simple clinical diagnostic tool to aid in the diagnosis and subtyping of EB.
METHODS: We developed a matrix indicating presence or absence of a set of distinctive clinical features (as rows) for the nine most prevalent EB subtypes (as columns). To test an individual patient, presence or absence of these features was compared with the findings expected in each of the nine subtypes to see which corresponded best. If two or more diagnoses scored equally, the diagnosis with the greatest number of specific features was selected. The matrix was tested using findings from 74 genetically characterized patients with EB aged > 6 months by an investigator blinded to molecular diagnosis. For concordance, matrix diagnoses were compared with molecular diagnoses.
RESULTS: Overall, concordance between the matrix and molecular diagnoses for the four major types of EB was 91·9%, with a kappa coefficient of 0·88 [95% confidence interval (CI) 0·81-0·95; P < 0·001]. The matrix achieved a 75·7% agreement in classifying EB into its nine subtypes, with a kappa coefficient of 0·73 (95% CI 0·69-0·77; P < 0·001).
CONCLUSIONS: The matrix appears to be simple, valid and useful in predicting the type and subtype of EB. An electronic version will facilitate further testing.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 27925151     DOI: 10.1111/bjd.15221

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

Authors:  Amy S Paller; John Browning; Milos Nikolic; Christine Bodemer; Dedee F Murrell; Willistine Lenon; Eva Krusinska; Allen Reha; Hjalmar Lagast; Jay A Barth
Journal:  Orphanet J Rare Dis       Date:  2020-06-23       Impact factor: 4.123

2.  Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa.

Authors:  C Has; L Liu; M C Bolling; A V Charlesworth; M El Hachem; M J Escámez; I Fuentes; S Büchel; R Hiremagalore; G Pohla-Gubo; P C van den Akker; K Wertheim-Tysarowska; G Zambruno
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

3.  Whole exome sequencing identified a novel compound heterozygous variation in COL7A1 gene causing dystrophic epidermolysis bullosa.

Authors:  Li-Min Cui; Jian-Ye Jiang; Ning-Ning Hu; Hong-En Zou; Bao-Zhen Zhao; Cong-Ying Han; Kai Yang; Yi-Peng Wang; Huan-Xia Xing
Journal:  Mol Genet Genomic Med       Date:  2022-02-28       Impact factor: 2.473

4.  Kidney and Urinary Tract Involvement in Epidermolysis Bullosa: Is Routine Follow-Up Necessary?

Authors:  Neslihan Cicek; Nurdan Yildiz; Ruslan Asadov; Ayse Deniz Yucelten; Halil Tugtepe; Harika Alpay
Journal:  Dermatol Pract Concept       Date:  2021-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.